Printer Friendly

CEPHALON INITIATES CLINICAL TRIALS OF MYOTROPHIN(TM) IN ALS PATIENTS

 CEPHALON INITIATES CLINICAL TRIALS OF MYOTROPHIN(TM)
 IN ALS PATIENTS
 WEST CHESTER, Pa., Aug. 27 /PRNewswire/ -- Cephalon, Inc. (NASDAQ: CEPH) announced today the initiation of its clinical testing program in the United States for Myotrophin(TM) in amyotrophic lateral sclerosis (ALS) patients. The program will be conducted in two stages beginning today with an open-label study in a select ALS patient population. The program is planned to expand into a double-blind, placebo-controlled Phase II trial at major ALS clinics across the United States. Ultimately, 150 patients are expected to participate in these trials.
 In May of this year, the company completed Phase I dose-ranging studies of Myotrophin in 48 normal, healthy volunteers in the United Kingdom. The company expects to initiate the second phase of its European ALS clinical testing program of Myotrophin in early 1993.
 "Our strategy of initiating Phase I clinical studies in normal, healthy volunteers in Europe allows us to select appropriate dose levels of Myotrophin for conducting studies in ALS patients," indicated Dr. Frank Baldino, Jr., president and CEO of Cephalon, Inc. "The preclinical and human safety data generated by Cephalon and others in the neuroscience community encourages our continued development of Myotrophin."
 Characterized by the progressive degeneration of motor neurons, ALS, also known as Lou Gehrig's disease, is a fatal disease affecting approximately 25,000-30,000 patients in the United States. The disease progresses over a three to five year period, with death typically occurring due to a loss of respiratory muscle control rendering the patient unable to breathe. Currently, there is no effective therapy for this devastating disease.
 Cephalon, Inc. focuses on the development of products to treat neurodegenerative diseases. These diseases are characterized by the death of neurons, specialized conducting cells of the nervous system. The company has concentrated its research programs on the prevention of neuronal death in several disorders, including ALS, Alzheimer's disease, head and spinal cord injuries, stroke, peripheral neuropathy and retinopathy.
 -0- 8/27/92
 /CONTACT: Nicole Vitullo, director of corporate communications of Cephalon, 215-344-0200, or Karen Bergman of Burns McClellan, 212-505-1919, for Cephalon/
 (CEPH) CO: Cephalon, Inc. ST: Pennsylvania IN: MTC SU: PDT


TM-PS -- NY001 -- 3776 08/27/92 08:36 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Aug 27, 1992
Words:364
Previous Article:MYCOGEN AND LUBRIZOL SIGN DEFINITIVE AGREEMENTS TO FORM A CROP PROTECTION PARTNERSHIP
Next Article:AIR CANADA AND AIR PARTNERS, L.P. MAKE OFFER TO INVEST US$400 MILLION IN CONTINENTAL AIRLINES
Topics:


Related Articles
CEPHALON, INC.'S MYOTROPHIN(TM) DEMONSTRATES SAFETY IN PHASE I TRIALS
CEPHALON INITIATES EUROPEAN PHASE II/III CLINICAL TRIAL OF MYOTROPHIN(TM)
CEPHALON BEGINS MYOTROPHIN CLINICAL TRIALS IN JAPAN
CEPHALON BEGINS PHASE III MODAFINIL CLINICAL TRIALS
CEPHALON COMPLETES INITIAL PHASE II/III CLINICAL TRIAL OF MYOTROPHIN(TM) IN ALS
CEPHALON REPORTS MYOTROPHIN (rhIGF-1) SLOWS PROGRESSION OF LOU GEHRIG'S DISEASE; CLINICAL STUDY DEMONSTRATES POSITIVE IMPACT ON DISABILITY
CEPHALON SUBMITS TREATMENT IND FOR MYOTROPHIN TO FDA
MYOTROPHIN CLINICAL TRIAL DATA TO BE PRESENTED AT MEETINGS IN DUBLIN, IRELAND, AND WASHINGTON, DC
MYOTROPHIN SCHEDULED FOR JUNE FDA ADVISORY PANEL MEETING
FDA CLEARS MYOTROPHIN EARLY ACCESS PROGRAM FOR PATIENTS WITH ALS

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters